Mireca Medicines Gmbh

Graybug Vision, Inc.

Biolog Life Science Institute Gmbh & Co. Kg

Andreas Rentsch

Hans-Gottfried Genieser

Frank Schwede

Valeria Marigo

Per Ekström

Pieter Jaap Gaillard

Francois Paquet-Durand

François Paquet-Durand

Dragana Trifunovic

Ayse Sahaboglu Tekgoz

Embodiments of the invention are directed to new polymer linked multimeric guanosine-3',5′-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being activators of cGMP dependent protein kinase (PKG), and related monomeric precursors thereof. The invention is also directed to related monomeric compounds, which may also show modulating activity and/or may serve as monomeric precursors of the multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces.

Polymer linked multimers of guanosine-3', 5′-cyclic monophosphates

Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5&#x2032;-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.

Equatorially modified polymer linked multimers of guanosine-3', 5&#x2032;-cyclic monophosphates

Cyclic dinucleotides are described, which in contrast to their natural congeners carry lipophilic nucleobases and have higher membrane permeability and increased biological activity.

Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3', 5&#x2032;-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

Targeted liposomal delivery of cGMP analogues

Growing community of inventors

Bremen, Germany

Andreas Rentsch